Last 61.35 INR
Change Today 0.00 / 0.00%
Volume 0.0
BLIS On Other Exchanges
Symbol
Exchange
BLIS is not on other exchanges.
As of 7:05 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

bliss gvs pharma ltd (BLIS) Snapshot

Open
63.00
Previous Close
62.65
Day High
64.90
Day Low
60.40
52 Week High
09/9/14 - 76.70
52 Week Low
11/1/13 - 27.65
Market Cap
6.3B
Average Volume 10 Days
547.8K
EPS TTM
3.97
Shares Outstanding
103.1M
EX-Date
08/13/14
P/E TM
15.5x
Dividend
0.50
Dividend Yield
0.81%
Current Stock Chart for BLISS GVS PHARMA LTD (BLIS)

Related News

No related news articles were found.

bliss gvs pharma ltd (BLIS) Related Businessweek News

No Related Businessweek News Found

bliss gvs pharma ltd (BLIS) Details

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India and internationally. The company offers therapeutic products, such as anti-fungal, laxative, anti-haemorrhoidal, anti-spasmodic, anti-malarial, anti-biotic, anti-microbial, anthelmintic, anti-diarrhoeal, anti-inflammatory, anti-pyretic, analgesic, anti-diabetic, anti-hypertensive, anti-emetic, anti-depressant, erectile dysfunction, multivitamin, anti-allergic, and antacid. It also provides over-the counter products, including herbal lozenges, shampoos, medicated dusting powders, herbal roll on products, and medicated and moisturizing soaps. In addition, the company provides female contraceptive under the Today brand name; and contract manufacturing services, as well as trades in pharmaceuticals. The company offers its products in various dosage forms, such as suppositories; pessaries; tablets; capsules; suspensions; syrups; dry powder injectables; injectables in ampoules; eye/ear/nasal drops; soft gelatin capsules; creams, gels, and ointments; and transdermal patches. The company was incorporated in 1984 and is based in Mumbai, India.

Founded in 1984

bliss gvs pharma ltd (BLIS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bliss gvs pharma ltd (BLIS) Key Developments

Bliss Gvs Pharma Limited Approves Dividend

Bliss Gvs Pharma Limited approved dividend at 50% that is INR 0.50 per share, at the AGM held on August 28, 2014.

Bliss Gvs Pharma Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2014

Bliss Gvs Pharma Limited reported unaudited standalone earnings results for the first quarter ended June 30, 2014. For the quarter, the company reported total income from operations (net) of INR 708.699 million compared to INR 755.767 million a year ago. Profit from operations before other income & finance cost & exceptional items was INR 203.211 million compared to INR 121.613 million a year ago. Profit from ordinary activities before tax was INR 205.802 million compared to INR 264.498 million a year ago. Net profit was INR 139.945 million compared to INR 182.504 million a year ago.

Bliss Gvs Pharma Limited, Board Meeting, Aug 28, 2014

Bliss Gvs Pharma Limited, Board Meeting, Aug 28, 2014. Agenda: To consider about AGM.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLIS:IN 61.35 INR 0.00

BLIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BLIS.
View Industry Companies
 

Industry Analysis

BLIS

Industry Average

Valuation BLIS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BLISS GVS PHARMA LTD, please visit www.blissgvspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.